Reimbursement Review Reports


( Last Updated : August 1, 2021)

The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

 

Brand Name Sort descending Generic name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
Avastin Bevacizumab Withdrawn Dec 16, 2016
Avastin Bevacizumab Platinum Resistant Ovarian Cancer Reimburse with clinical criteria and/or conditions Complete Oct 29, 2015 May 5, 2016
Avastin Bevacizumab Cervical Cancer Reimburse with clinical criteria and/or conditions Complete Oct 27, 2014 Mar 23, 2015
Avastin Bevacizumab Ovarian Cancer Reimburse with clinical criteria and/or conditions Complete Nov 28, 2014 Jun 4, 2015
Avastin (with capecitabine) Bevacizumab Metastatic Colorectal Cancer Reimburse with clinical criteria and/or conditions Complete Feb 18, 2015 Jul 21, 2015
Bavencio Avelumab Urothelial Carcinoma (UC) Complete Sep 18, 2020 Mar 23, 2021
Bavencio Avelumab metastatic Merkel Cell Carcinoma (mMCC) Reimburse with clinical criteria and/or conditions Complete Oct 10, 2017 Mar 21, 2018
Beleodaq Belinostat Withdrawn Jun 29, 2018
Besponsa Inotuzumab Ozogamicin Acute Lymphoblastic Leukemia (ALL) Reimburse with clinical criteria and/or conditions Complete Nov 13, 2017 Jul 6, 2018
Blincyto Blinatumomab Acute Lymphoblastic Leukemia Reimburse with clinical criteria and/or conditions Complete Aug 24, 2015 Apr 1, 2016